Patient-Reported Outcomes After a Switch to a Single-Tablet Regimen of Rilpivirine, Emtricitabine, and Tenofovir DF in HIV-1-Positive, Virologically Suppressed Individuals: Additional Findings From a Randomized, Open-Label, 48-Week Trial
Crossref DOI link: https://doi.org/10.1007/s40271-015-0123-2
Published Online: 2015-03-26
Published Print: 2015-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Brunetta, Jason
Moreno Guillén, Santiago
Antinori, Andrea
Yeni, Patrick
Wade, Barbara
Johnson, Margaret
Shalit, Peter
Ebrahimi, Ramin
Johnson, Bethsheba
Walker, Ivan
De-Oertel, Shampa
License valid from 2015-03-26